相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities
Michelle Head et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Currently approved prophylactic HPV vaccines
Diane M. Harper
EXPERT REVIEW OF VACCINES (2009)
Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs
L. -C. Steve Wang et al.
INVESTIGATIONAL NEW DRUGS (2009)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800 mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer
Mark J. McKeage et al.
LUNG CANCER (2009)
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia.
Gemma G. Kenter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Synthetic Double-Stranded RNAs Are Adjuvants for the Induction of T Helper 1 and Humoral Immune Responses to Human Papillomavirus in Rhesus Macaques
Christiane Stahl-Hennig et al.
PLOS PATHOGENS (2009)
Induction of tumor-specific CD4+ and CD8+ T-Cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine
Marij J. P. Welters et al.
CLINICAL CANCER RESEARCH (2008)
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows lowtoxicity and robust immunogenicity
Gemma G. Kenter et al.
CLINICAL CANCER RESEARCH (2008)
Therapeutic human papillomavirus vaccines: current clinical trials and future directions
Chien-Fu Hung et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines
Cornelis J. M. Melief et al.
NATURE REVIEWS CANCER (2008)
Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency
Bruce Huang et al.
VACCINE (2007)
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection - A randomized trial
Allan Hildesheim et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes
Africa Wallace et al.
CANCER RESEARCH (2007)
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Suzanne M. Garland et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Small molecule vascular disrupting agents: Potential new drugs for cancer treatment
Sui X. Cai
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2007)
Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant:: therapeutic activity against human cervical cancer in a rodent model
Zhengrong Cui et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
DM Harper et al.
LANCET (2006)
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent
M McKeage et al.
CLINICAL CANCER RESEARCH (2006)
Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model
A Vambutas et al.
VACCINE (2005)
Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy
LD McPhail et al.
CLINICAL CANCER RESEARCH (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Advances in imaging mouse tumour models in vivo
SK Lyons
JOURNAL OF PATHOLOGY (2005)
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
DM Harper et al.
LANCET (2004)
Comparison of HPV DNA vaccines employing intracellular targeting strategies
JW Kim et al.
GENE THERAPY (2004)
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides
S Zwaveling et al.
JOURNAL OF IMMUNOLOGY (2002)
The causal relation between human papillomavirus and cervical cancer
FX Bosch et al.
JOURNAL OF CLINICAL PATHOLOGY (2002)
Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen
CF Hung et al.
JOURNAL OF IMMUNOLOGY (2001)
分享论文
